XORTX Therapeutics Inc
XRTX0.560USD
-0.016-2.74%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
2.92MMarket Cap
LossP/E TTM
More Details of XORTX Therapeutics Inc Company
XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.
XORTX Therapeutics Inc Info
Ticker SymbolXRTX
Company nameXORTX Therapeutics Inc
IPO dateSep 30, 2015
CEODavidoff (Allen W)
Number of employees2
Security typeOrdinary Share
Fiscal year-endSep 30
Address3710 - 33rd Street NW
CityCALGARY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCanada
Postal codeT2L 2M1
Phone14034557727
Websitehttps://www.xortx.com/
Ticker SymbolXRTX
IPO dateSep 30, 2015
CEODavidoff (Allen W)
Company Executives of XORTX Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Michael Bumby
Mr. Michael Bumby
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Paul J. Van Damme
Mr. Paul J. Van Damme
Independent Director
Independent Director
--
--
Dr. Stephen Haworth
Dr. Stephen Haworth
Chief Medical Officer
Chief Medical Officer
--
--
Mr. William (Bill) Farley
Mr. William (Bill) Farley
Independent Director
Independent Director
--
--
Mr. Patrick Treanor
Mr. Patrick Treanor
Independent Director
Independent Director
--
--
Dr. Allen W. Davidoff, Ph.D.
Dr. Allen W. Davidoff, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Anthony J. Giovinazzo
Mr. Anthony J. Giovinazzo
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Ms. Abigail Jenkins
Ms. Abigail Jenkins
Independent Director
Independent Director
--
--
Mr. Stacy Evans, M.D.
Mr. Stacy Evans, M.D.
Chief Business Officer
Chief Business Officer
--
--
Dr. Raymond Dennis (Ray) Pratt, M.D.
Dr. Raymond Dennis (Ray) Pratt, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Michael Bumby
Mr. Michael Bumby
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Paul J. Van Damme
Mr. Paul J. Van Damme
Independent Director
Independent Director
--
--
Dr. Stephen Haworth
Dr. Stephen Haworth
Chief Medical Officer
Chief Medical Officer
--
--
Mr. William (Bill) Farley
Mr. William (Bill) Farley
Independent Director
Independent Director
--
--
Mr. Patrick Treanor
Mr. Patrick Treanor
Independent Director
Independent Director
--
--
Dr. Allen W. Davidoff, Ph.D.
Dr. Allen W. Davidoff, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Lincoln Alternative Strategies LLC
8.22%
Davidoff, Allen Warren
1.73%
Citadel Advisors LLC
1.24%
XTX Markets LLC
0.20%
Giovinazzo (Anthony)
0.14%
Other
88.47%
Shareholders
Shareholders
Proportion
Lincoln Alternative Strategies LLC
8.22%
Davidoff, Allen Warren
1.73%
Citadel Advisors LLC
1.24%
XTX Markets LLC
0.20%
Giovinazzo (Anthony)
0.14%
Other
88.47%
Shareholder Types
Shareholders
Proportion
Corporation
8.22%
Individual Investor
1.87%
Hedge Fund
1.24%
Venture Capital
0.20%
Other
88.47%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
16
63.97K
1.23%
-645.66K
2025Q2
17
129.44K
3.30%
-739.58K
2025Q1
20
127.29K
3.49%
-606.22K
2024Q4
21
385.20K
10.34%
-244.07K
2024Q3
22
287.39K
12.35%
-145.77K
2024Q2
20
276.67K
12.12%
-141.93K
2024Q1
21
272.84K
13.24%
-121.02K
2023Q4
19
553.49K
27.69%
+481.09K
2023Q3
20
176.53K
8.83%
-185.14K
2023Q2
19
179.60K
8.98%
-178.94K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Davidoff, Allen Warren
120.45K
2.31%
+8.19K
+7.30%
Jul 22, 2025
Citadel Advisors LLC
38.47K
0.74%
+38.47K
--
Jun 30, 2025
Giovinazzo (Anthony)
9.63K
0.18%
--
--
Apr 30, 2025
RBC Dominion Securities, Inc.
--
0%
-1.49K
-100.00%
Mar 31, 2025
Van Damme (Paul Joseph)
7.11K
0.14%
--
--
Apr 30, 2025
Clearstead Advisors LLC
277.00
0.01%
--
--
Jun 30, 2025
UBS Financial Services, Inc.
20.79K
0.4%
+20.79K
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Date
Type
Ratio
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
FAQs
Who are the top five shareholders of XORTX Therapeutics Inc?
The top five shareholders of XORTX Therapeutics Inc are:
Davidoff, Allen Warren holds 120.45K shares, accounting for 2.31% of the total shares.
Citadel Advisors LLC holds 38.47K shares, accounting for 0.74% of the total shares.
Giovinazzo (Anthony) holds 9.63K shares, accounting for 0.18% of the total shares.
RBC Dominion Securities, Inc. holds 0.00 shares, accounting for 0.00% of the total shares.
Van Damme (Paul Joseph) holds 7.11K shares, accounting for 0.14% of the total shares.
Davidoff, Allen Warren holds 120.45K shares, accounting for 2.31% of the total shares.
Citadel Advisors LLC holds 38.47K shares, accounting for 0.74% of the total shares.
Giovinazzo (Anthony) holds 9.63K shares, accounting for 0.18% of the total shares.
RBC Dominion Securities, Inc. holds 0.00 shares, accounting for 0.00% of the total shares.
Van Damme (Paul Joseph) holds 7.11K shares, accounting for 0.14% of the total shares.
What are the top three shareholder types of XORTX Therapeutics Inc?
The top three shareholder types of XORTX Therapeutics Inc are:
Lincoln Alternative Strategies LLC
Davidoff, Allen Warren
Citadel Advisors LLC
Lincoln Alternative Strategies LLC
Davidoff, Allen Warren
Citadel Advisors LLC
How many institutions hold shares of XORTX Therapeutics Inc (XRTX)?
As of 2025Q3, 16 institutions hold shares of XORTX Therapeutics Inc, with a combined market value of approximately 63.97K, accounting for 1.23% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -2.08%.
What is the biggest source of revenue for XORTX Therapeutics Inc?
In --, the -- business generated the highest revenue for XORTX Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
